coronary angiography News
-
CathWorks FFRangio System Receives National Reimbursement Approval in Japan
CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio™ System, making it more broadly available for coronary artery disease decision-making in Japan. The CathWorks FFRangio™ System has already received regulatory approval from the Japanese Pharmaceuticals and Medical Devices ...
By CathWorks
-
CathWorks FFRangio System Receives Regulatory Approval in Japan
CathWorks today announced the approval of The CathWorks FFRangio™ System by the Japan’s Ministry of Health, Labour and Welfare (MHLW). The CathWorks FFRangio System is a non-invasive diagnostic technology that is used at the time of a routine angiography. The CathWorks FFRangio System transforms routine angiogram images into objective and comprehensive physiology information, ...
By CathWorks
-
Arterius Welcomes New Clinical Advisers
Arterius are pleased to welcome Prof. Patrick Serruys and Dr. Yoshi Onuma to our clinical advisory board. Prof. Serruys (Imperial College, London) will become chair of the clinical advisory board, also now featuring Dr. Onuma (Cardialysis, Netherlands) and Dr. Rasha Al-Lamee (Imperial College, London). Prof. Patrick W. Serruys is is a professor of Interventional Cardiology at the ...
-
Mike Feher Appointed as CFO of CathWorks
CathWorks, a global leader of digital health innovation focused on helping patients with cardiovascular disease, announced today that Mike Feher was appointed Chief Financial Officer, effective immediately. An energetic and results-driven executive, Mr. Feher brings comprehensive strategic and operational finance experience to his role, including expertise in financial planning and analysis, ...
By CathWorks
-
CathWorks FFRangio System outcomes study to be presented at ACC 2022
CathWorks announced today that the results of its most recent outcomes study on the CathWorks FFRangio™ system will be presented by Dr. Guy Witberg from Rabin Medical Center, Petah Tikva, Israel on Sunday, April 3 at the annual American College of Cardiology (ACC) conference in Washington, DC. Dr. Witberg and his co-investigators in Israel and Japan examined the 1-year clinical outcomes of ...
By CathWorks
-
Soundbite Medical Announces Issuance Of A Fifth U.S. Patent Covering Novel Active Balloon Devices Intended For Plaque Modification Of Calcified Arteries
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that the United States Patent and Trademark Office has issued US patent No. 11,179,169, entitled “Device for delivering mechanical waves through a balloon catheter”. The ...
-
CathWorks Adds Vice President of Global Marketing to Leadership Team
CathWorks announced that Ramin Mousavi has joined CathWorks as Vice President of Global Marketing & Strategy. Mr. Mousavi, an experienced cardiovascular marketer, will take responsibility for the CathWorks FFRangio™ System U.S. clinical and commercial launch and direct future expansion into other global markets. Mr. Mousavi has over 15 years of global marketing, strategy, product ...
By CathWorks
-
CathWorks Announces Appointment of Ramin Mousavi as Chief Executive Officer and Board Member
CathWorks , a global leader of digital health innovation focused on helping patients with cardiovascular disease, today announced that Ramin Mousavi has been appointed Chief Executive Officer, effective June 21, 2021. Mr. Mousavi has also been appointed to the company’s Board of Directors. Mr. Mousavi succeeds Jim Corbett, who served as the company’s CEO since October 27, 2017. A ...
By CathWorks
-
GE Healthcare to Distribute Osprey Medical’s Technology to Address Angiography Based Acute Kidney Injury (AKI)
GE Healthcare and Osprey Medical Inc. (ASX:OSP) (Osprey) today announced a strategic alliance under which GE Healthcare will exclusively distribute Osprey’s product portfolio in Europe, Russia, Middle East, Africa, Central Asia and Turkey. Osprey’s DyeVert™ contrast minimization devices, complemented by GE Healthcare's range of iodinated x-ray contrast media, offer healthcare ...
-
Kardiolytics’ VCAST Technology Offers Non-Invasive and Safe Solution for Functional Evaluation of Coronary Disease, According to Recent Study in Cardiovascular Engineering and Technology
Our latest publication in Cardiovascular Engineering and Technology showcases the feasibility and functionality of our VCAST technology, a patented, AI-based medical system developed for non-invasive, clinical quantitative and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. Using a ...
-
Osprey Medical, Inc. Awarded Premier Purchasing Agreement for DyeVert™ PLUS Contrast Reduction System
Osprey Medical (ASX: OSP) today is announcing that its DyeVert Plus Contrast Reduction System was awarded a group purchasing agreement as a Technology Breakthroughs award with Premier Inc. (Premier), a leading healthcare improvement company. Osprey Medical’s DyeVert Plus System is the only technology cleared by the U. S. Food & Drug Administration for contrast reduction and real-time ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you